2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
255
Breast Neoplasms
218
Lung Neoplasms
206
Glioblastoma
202
Head and Neck Neoplasms
193
Prostatic Neoplasms
179
Squamous Cell Carcinoma of Head and Neck
171
Lymphoma
152
Rectal Neoplasms
138
Esophageal Neoplasms
125
Central Nervous System Neoplasms
122
Leukemia
111
Brain Neoplasms
106
Pancreatic Neoplasms
96
Precursor Cell Lymphoblastic Leukemia-Lymphoma
93
Gliosarcoma
87
Esophageal Squamous Cell Carcinoma
84
Sarcoma
82
Uterine Cervical Neoplasms
81
Lymphoma, Follicular
81
Neoplasms
80
Lymphoma, Large B-Cell, Diffuse
80
Lymphoma, Non-Hodgkin
75
Hodgkin Disease
74
Glioma
68
Burkitt Lymphoma
67
Colorectal Neoplasms
66
Leukemia, Lymphocytic, Chronic, B-Cell
63
Astrocytoma
63
Neoplasm Metastasis
60
Interventions
Vincristine
2
Temozolomide
2
Oncolytic Virotherapy
2
vorasidenib
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
lutetium Lu 177 dotatate
1
interferon gamma-1b
1
copper dotatate CU-64
1
cixutumumab
1
Vorinostat
1
Valproic Acid
1
Thiotepa
1
Sunitinib
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lutetium-177
1
Lutetium
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors
×
Radiotherapy
×
Clear all
NCT01614132
2020-03-31
NOA-07
University of Regensburg
Phase 1/2
Completed
33 enrolled